+ Filter
Loading...
Custom Services order now ship next day

Anti-MERTK Recombinant Antibody Products

Loading...

Anti-MERTK Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs offers advanced recombinant antibodies targeting MERTK, supporting the progress of biomedical research. Through cutting-edge technology platforms, we ensure each product upholds strict standards of quality and performance. Our broad portfolio reflects a strong commitment to research advancement, delivering reliable and cost-effective solutions. In addition to high-performance antibodies, we provide expert technical assistance to support scientists throughout their projects. Partnering with Creative Biolabs means gaining access to innovative tools and a dependable ally in your research efforts.

MERTK: A Crucial target in Autoimmune Disorders and Inflammatory Diseases

MERTK is a receptor tyrosine kinase that plays a critical role in immune regulation, tissue homeostasis, and the clearance of apoptotic cells. Dysregulation or overexpression of MERTK has been implicated in various diseases, including cancers such as leukemia and non-small cell lung cancer, as well as autoimmune and inflammatory disorders like systemic lupus erythematosus and rheumatoid arthritis. In cancer, MERTK contributes to tumor growth, survival, and resistance to therapy by promoting immune evasion and supporting oncogenic signaling pathways. In autoimmune diseases, improper MERTK signaling can impair the removal of dying cells, leading to chronic inflammation. Due to its involvement in both immune dysfunction and tumor progression, MERTK is considered a promising therapeutic target in oncology and immunology.

Alternative Names

Complement MERTK; MER proto-oncogene, tyrosine kinase; MER; RP38; c-Eyk; c-mer; Tyro12

Background

This gene is a member of the MER/AXL/TYRO3 receptor kinase family and encodes a transmembrane protein with two fibronectin type-III domains, two Ig-like C2-type (immunoglobulin-like) domains, and one tyrosine kinase domain. Mutations in this gene have been associated with disruption of the retinal pigment epithelium (RPE) phagocytosis pathway and onset of autosomal recessive retinitis pigmentosa (RP).

Protein class

Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets

Predicted location

Intracellular, Membrane (different isoforms)

Single cell type specificity

Cell type enhanced (Astrocytes, Microglial cells, Kupffer cells, Macrophages)

Immune cell specificity

Group enriched (intermediate monocyte, non-classical monocyte)

Cell line specificity

Cell line enhanced (CACO-2, Hep G2, HUVEC TERT2, RT4)

Interaction

Interacts (upon activation) with TNK2; stimulates TNK2 autophosphorylation. Interacts (via N-terminus) with extracellular ligands LGALS3, TUB, TULP1 and GAS6 (By similarity). Interacts with VAV1 in a phosphotyrosine-independent manner. Interacts with TIMD4; this interaction enhances TIMD4-mediated efferocytosis (PubMed:32640697).

Molecular function

Kinase, Receptor, Transferase, Tyrosine-protein kinase

More Types Infomation

Anti-MERTK rAb Products

We are dedicated to advancing research and innovation by delivering high-quality anti-MERTK recombinant antibodies, combined with strong technical support and cost-effective solutions. Our goal is to help researchers move their projects forward efficiently and with confidence.

Cat. No. Product Name Target Species Host Species Applications
MOB-4080z Mouse Anti-MERTK Recombinant Antibody (clone 28A5) Human Mouse WB; ELISA; IP
MOB-1466MZ Recombinant Mouse Anti-Human MERTK Antibody (clone B422G0H4) Human Mouse WB
NEUT-1725CQ Recombinant Mouse Anti-MERTK Antibody (NEUT-1725CQ) Human Mouse WB; Block; IP; IHC-P
HPAB-0215-CN Mouse Anti-MERTK Recombinant Antibody (HPAB-0215-CN) Human; Mouse Mouse WB; ELISA
ZG-0138U Human Anti-MERTK Recombinant Antibody (clone 8H11) Human Human ELISA

Creative Quality Control

To support the advancement of biopharmaceutical research through to commercialization, we prioritize a customer-focused approach, emphasizing the delivery of high-quality products. A robust quality management system has been established to ensure consistency and reliability. By consistently meeting — and often exceeding — customer expectations, we strive to streamline the drug development process and help our clients reduce time to market.

ELISA analysis of ZG-0138U. (Creative Biolabs Original)Fig.1 ELISA analysis of anti-MERTK antibody
(Cat# ZG-0138U, Creative Biolabs).

Customer Reviews

Excellent
S**ia
Human Anti-MERTK Recombinant Antibody (clone 8H11) (CAT#: ZG-0138U)
It performs well in detecting MERTK expression in HEK293 and A549 cell lines. I've used it in both ELISA and Western blot with good results—clear, specific bands and minimal background. It also works well in immunohistochemistry, although some optimization was required for certain tissues. Overall, it is reliable and provides consistent, reproducible results without being too expensive.
12/Mar/2024
Excellent
B**in
Mouse Anti-MERTK Recombinant Antibody (clone 28A5) (CAT#: MOB-4080z)
I tested it on THP-1 and RAW264.7 cells and found it worked well. It produced distinct, specific bands in both ELISA and Western blot, with minimal background noise. The antibody also worked on tissue samples, though some parameter tuning was necessary. Overall, it showed dependable and consistent performance.
18/Nov/2023

rAb Production

With years of experience in recombinant antibody development and optimization, we are committed to delivering high-quality products and efficient service. Our focus on excellence ensures reliable recombinant antibodies within a short turnaround time.

Featured Anti-MERTK Recombinant Antibody Production PlatformsAnti-MERTK recombinant antibody production: milligram-scale. (Creative Biolabs Original)
Fig.2 Milligram-scale recombinant antibody production.

Anti-MERTK recombinant antibody production: gram-scale. (Creative Biolabs Original)Fig.3 Gram-scale recombinant antibody production.

rAb Modalities

Creative Biolabs provides researchers with a broad selection of advanced, high-quality recombinant antibodies in multiple formats. We specialize in diverse antibody engineering techniques and offer customized services to meet specific project requirements.

Diverse anti-MERTK recombinant antibody production and modalities. (Creative Biolabs Original)Fig.4 Full Length Anti-MERTK Recombinant Antibody Production and Modalities.

Drug Information Targeting MERTK

Table 1. Therapeutic approaches targeting MERTK in clinical development.

Research phase Company Classification Indications Details
Phase III Exelixis Small Molecules Cancer; Solid tumor It is an oral next-generation tyrosine kinase inhibitor developed by Exelixis, currently in advanced clinical trials for various cancers, including metastatic colorectal cancer, non-clear cell renal cell carcinoma, and PD-L1 positive head and neck squamous cell carcinoma.
Phase III BeiGene Small Molecules Cancer; Solid tumor It is an oral multitargeted kinase inhibitor developed by Mirati Therapeutics, licensed to BeiGene, and evaluated in clinical trials for various advanced solid tumors, including non-small cell lung cancer and urothelial carcinoma.
Phase II Lilly Small Molecules Cancer; Solid tumor It is a human growth factor receptor inhibitor developed by Lilly, evaluated in clinical trials for various cancers including biliary tract adenocarcinoma and MET exon 14 mutant advanced non-small cell lung cancer.
Phase I/II Lead Discovery Center Small Molecules Cancer; Solid tumor It is an orally available triple kinase inhibitor developed by Qurient, targeting Axl, Mer, and CSF1R for the treatment of advanced solid tumors, including esophageal and gastric cancers.
Phase I/II SignalChem Lifesciences Small Molecules Cancer; Solid tumor It is an oral small-molecule AXL kinase inhibitor developed by SignalChem Lifesciences and Xuanzhu Biopharma for the treatment of advanced solid tumors, including non-small cell lung cancer and acute myeloid leukemia.
Phase I Ono Small Molecules Acute leukemia;
Cancer
It is an oral AXL and MERTK dual inhibitor developed by Ono for the treatment of EGFR-positive non-small cell lung cancer and pancreatic cancer.
Phase I King Faisal Specialist Hosp Res Centre Biologics Retinitis pigmentosa It is a gene therapy using rAAV2 encoding human MERTK, developed by KFSHRC for the treatment of retinitis pigmentosa.

If you need more details about the MERTK target, don't hesitate to contact us by phone or email. Our experienced team is happy to help with any questions or issues you encounter, providing the support necessary for your research success.

Go to compare

Go to compare